Results 71 to 80 of about 4,104 (188)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study

Endocrine Connections, 2019
Purpose: Little data are available regarding the safety and efficacy of s witching to Pasireotide-LAR monotherapy in acromegaly patients with partial resistance to first-generation somatostatin agonists (1gSRL) who require combination treatment with ...
Hélène Lasolle, Amandine Ferriere, Alexandre Vasiljevic, Sandrine Eimer, Marie-Laure Nunes, Antoine Tabarin   +5 more
doaj   +1 more source

Managing high blood sugar (hyperglycemia) during pasireotide treatment: A plain language summary of the B2219 study

Future Rare Diseases
Pasireotide is a medication used to treat people with acromegaly or Cushing's disease, both of which are hormonal disorders caused by a non-cancerous tumor (adenoma) in the pituitary gland.
S. L. Samson, U. Feldt-Rasmussen, Shao-Ling Zhang, Yerong Yu, P. Witek, Pramila Kalra, M. Bolanowski   +6 more
semanticscholar   +1 more source

Comprehensive mapping of somatotroph pituitary neuroendocrine tumour heterogeneity using spatial and single‐cell transcriptomics

Clinical and Translational Medicine, Volume 14, Issue 11, November 2024.
Abstract Background Pituitary neuroendocrine tumours (PitNETs) are common intracranial tumours that are highly heterogeneous with unpredictable growth patterns. The driver genes and mechanisms that are crucial for tumour progression in somatotroph PitNETs are poorly understood. Methods In this study, we performed integrative spatial transcriptomics (ST)
Jialin Wang, Xuejing Li, Jing Guo, Zan Yuan, Xinyu Tong, Zehao Xiao, Meng Liu, Changxiaofeng Liu, Hongyun Wang, Lei Gong, Chuzhong Li, Yazhuo Zhang, Weiyan Xie, Chunhui Liu   +13 more
wiley   +1 more source

New cross-roads for second line medical therapy in acromegaly [PDF]

Archives of the Balkan Medical Union, 2018
Acromegaly is a complex disorder caused by growth hormone excess mostly due to a pituitary adenoma. Surgery represents the first option but rate of long time success is almost 50% thus the patients need other therapies.
Adina Ghemigian, Andra Cocolos, Eugenia Petrova, Ana Valea, Nicoleta Dumitru, Mara Carsote   +5 more
doaj  

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion

Clinical Pharmacology: Advances and Applications, 2021
Alexia Rouland,1 Benjamin Bouillet,1,2 Pauline Legris,1 Isabelle Simoneau,2 Jean-Michel Petit,1,2 Bruno Vergès1,2 1Endocrinology Diabetics and Metabolic Disorders Department, Dijon University Hospital, Dijon, France; 2French National Health and ...
Rouland A, Bouillet B, Legris P, Simoneau I, Petit JM, Vergès B   +5 more
doaj  

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

BMC Endocrine Disorders, 2018
Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored.
A. Ciresi, S. Radellini, V. Guarnotta, C. Giordano   +3 more
doaj   +1 more source

FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond

Journal of Peptide Science, Volume 30, Issue 11, November 2024.
This review provides an overview of FDA‐approved peptides, particularly those targeting cardiovascular diseases, human immunodeficiency, and central nervous system diseases, and also addresses conditions such as osteoporosis, thrombocytopenia, Cushing's disease, and hypoglycemia.
Othman Al Musaimi
wiley   +1 more source

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation [PDF]

, 2021
Maria Stelmachowska‐Banaś, Izabella Czajka-Oraniec, Agnieszka Tomasik, Wojciech Zgliczyński   +3 more
openalex   +1 more source

Recent advances in the treatment of refractory gastrointestinal angiodysplasia

United European Gastroenterology Journal, Volume 12, Issue 8, Page 1128-1135, October 2024.
Abstract Gastrointestinal angiodysplasia (GIA) is a common, acquired, vascular abnormality of the digestive tract, and a frequent cause of bleeding. Refractory GIA criteria usually include recurrent bleeding, transfusions and/or repeat endoscopy. Pharmacological and interventional treatments have been the subject of recent high‐quality publications ...
Aymeric Becq, Reena Sidhu, Lia C. M. J. Goltstein, Xavier Dray   +3 more
wiley   +1 more source

New options for the medical treatment of Cushing′s syndrome

Indian Journal of Endocrinology and Metabolism, 2013
A number of drugs have been advocated for the medical management of Cushing′s syndrome but few have gained widespread acceptance. The most reliably effective agents are metyrapone and ketoconazole as monotherapy, or in combination.
Peter J Trainer
doaj   +1 more source